

The Merck Index - Microsoft Internet Explorer provided by USP 10

Back Forward Stop Refresh Home Search Favorites History Mail Print Document

Address http://thermindex.cdn.biosoft.com/TheMerckIndex/default.asp?imgroup=eserp_form_group&destination=4&id=merma=TheMerckIndex

Log On

The Merck Index

TAYLOR & FRANCIS

3 Current Session(s)
00763939

INTRODUCTION TOPPING SEARCH FORMULARY AND CAUTIONS ADDITIONAL TABLES SEARCH EXPANSION

Total Records: 11000
Total Hits: 1

File Query Help Mail Mail Mail Log Off

NEW QUERY Refine

Record 1 of 1: [Back](#) [Return to List](#)

Monograph number: 08122
Title: Rituximab
CAS Registry Number: 174722-31-7
CAS Name: Anti-(human CD20 antigen) immunoglobulin G1 (human-mouse monoclonal IDEC-C2B8 γ -chain) disulfide with human-mouse monoclonal IDEC-C2B8 κ -chain, dimer
Manufacturers' Codes: IDEC-C2B8
Trademarks: Mabthera (Roche), Rituxan (Genentech)
Literature References: Genetically engineered chimeric murine-human monoclonal antibody directed against the CD20 antigen found on normal and malignant B lymphocyte surfaces. Contains murine light and heavy-chain variable regions and γ , heavy-chain and κ light chain human constant regions. Composed of 2 heavy chains of 451 amino acids and 2 light chains of 213 amino acids; approx mol wt 145 kD. Prep: D. R. Anderson *et al.*, WO 9411026; *idem*, US 5763137 (1994, 1998 both to IDEC); M. E. Reif *et al.*, *Blood* 83, 435 (1994). HPLC determin of product purity: K. G. Moonhouse *et al.*, *J. Pharm. Biomed. Anal.* 16, 593 (1997). Clinical pharmacokinetics: N. L. Bernstein *et al.*, *Ann. Oncol.* 9, 995 (1998). Clinical trial in lymphoma: P. McLaughlin *et al.*, *J. Clin. Oncol.* 16, 2825 (1998); in combination with CHOP chemotherapy: M. S. Czuczman *et al.*, *ibid.* 17, 266 (1999). Review of clinical studies: C. A. White, *Cancer Biother. Radiopharm.* 14, 241-250 (1999); and pharmacology: S. V. Onnisi *et al.*, *Drugs* 58, 79-88 (1999). Clinical evaluation in hematologic autoimmune diseases: F. Zaja *et al.*, *Haematologica* 87, 169 (2002).
Therapeutic Category: Antineoplastic.

Copyright © 2001-2003 by Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved.

Start Stop Print Home Online Internet Explorer Documents

BEST AVAILABLE COPY

rituximab - Microsoft Internet Explorer provided by USP 10

File Edit View Favorites Tools Help

Address http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi

Google

National Library of Medicine - Medical Subject Headings

2006 MeSH

MeSH Supplementary Concept Data

[Return to Entry Page](#)

Name of Substance	rituximab
Record Type	C
Registry Number	0
Entry Term	IDEC-C2B8
Entry Term	Rituxan
Entry Term	IDEC-C2B8 antibody
Entry Term	Mabthera
Entry Term	Roche brand of rituximab
Entry Term	Genentech brand of rituximab
Entry Term	Hoffmann-La Roche brand of rituximab
Entry Term	IDEC brand of rituximab
Heading Mapped to	*Antibodies, Monoclonal
Indexing Information	Lymphoma, B-Cell
Source	Oncology (Huntingt) 1994 Dec;8(12):84, S7
Thesaurus ID	AU Australian Trade Name
Thesaurus ID	CA Canadian Trade Name
Thesaurus ID	DE German Trade Name
Thesaurus ID	FR French Trade Name
Thesaurus ID	MX Mexican Trade Name
Thesaurus ID	UK United Kingdom Trade Name
Thesaurus ID	US United States Trade Name
Pharm. Action	Antineoplastic Agents
Pharm. Action	Immunologic Factors
Frequency	1656
Note	a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma
Date of Entry	19950417
Revision Date	20050622
Unique ID	C092560

[Return to Entry Page](#) [Link to NLM Cataloging Classification](#)

Done

File Edit View Favorites Tools Help

Address http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi

Google

BEST AVAILABLE COPY